Emicizumab was approved as a first-line therapy for severe bleeding disorders in 2017. According to a study, infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications.
![Blood Vial](https://alumni.umich.edu/wp-content/uploads/blood_vial-1.png)
•
Read time:
Emicizumab was approved as a first-line therapy for severe bleeding disorders in 2017. According to a study, infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications.